429 related articles for article (PubMed ID: 19597464)
21. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Hellström-Lindberg E; Wainscoat JS
Br J Haematol; 2007 Nov; 139(4):578-89. PubMed ID: 17916100
[TBL] [Abstract][Full Text] [Related]
22. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
Keerthivasan G; Mei Y; Zhao B; Zhang L; Harris CE; Gao J; Basiorka AA; Schipma MJ; McElherne J; Yang J; Verma AK; Pellagatti A; Boultwood J; List AF; Williams DA; Ji P
Blood; 2014 Jul; 124(5):780-90. PubMed ID: 24891322
[TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
24. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
25. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
[TBL] [Abstract][Full Text] [Related]
26. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
[TBL] [Abstract][Full Text] [Related]
27. Novel genes mapping to the critical region of the 5q- syndrome.
Boultwood J; Fidler C; Soularue P; Strickson AJ; Kostrzewa M; Jaju RJ; Cotter FE; Fairweather N; Monaco AP; Müller U; Lovett M; Jabs EW; Auffray C; Wainscoat JS
Genomics; 1997 Oct; 45(1):88-96. PubMed ID: 9339364
[TBL] [Abstract][Full Text] [Related]
28. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
29. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
35. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
36. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).
Lai F; Godley LA; Joslin J; Fernald AA; Liu J; Espinosa R; Zhao N; Pamintuan L; Till BG; Larson RA; Qian Z; Le Beau MM
Genomics; 2001 Jan; 71(2):235-45. PubMed ID: 11161817
[TBL] [Abstract][Full Text] [Related]
37. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q.
Gao Q; Horwitz M; Roulston D; Hagos F; Zhao N; Freireich EJ; Golomb HM; Olopade OI
Genes Chromosomes Cancer; 2000 Jun; 28(2):164-72. PubMed ID: 10825001
[TBL] [Abstract][Full Text] [Related]
38. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
Zatkova A; Merk S; Wendehack M; Bilban M; Muzik EM; Muradyan A; Haferlach C; Haferlach T; Wimmer K; Fonatsch C; Ullmann R
Genes Chromosomes Cancer; 2009 Jun; 48(6):510-20. PubMed ID: 19306356
[TBL] [Abstract][Full Text] [Related]
39. Cryptic deletion of EGR1 in association with a novel balanced t(5;22)(q31;q11.2) in a patient with myelodysplastic syndrome.
Hoffman MW; Janney S; Batanian JR
Cancer Genet Cytogenet; 2009 Jun; 191(2):106-8. PubMed ID: 19446747
[TBL] [Abstract][Full Text] [Related]
40. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
